STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

[Form 4] Beta Bionics, Inc. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions dated 10/03/2025. He acquired 4,982 shares on that date through exercise of an employee stock option with an exercise price of $5.10, bringing his beneficial ownership to 49,023 shares immediately after the acquisition. On the same date he sold 3,828 shares at a weighted average price of $21.5172 and 1,154 shares at a weighted average price of $22.2778, executed pursuant to a Rule 10b5-1 plan adopted on 05/15/2025. After these transactions his reported beneficial ownership is 44,041 shares. The option shares vest in 48 equal monthly installments measured from 09/14/2023.

Stephen Feider, Chief Financial Officer di Beta Bionics, Inc. (BBNX), ha riportato transazioni insider datate 10/03/2025. Ha acquistato 4.982 azioni in quella data mediante l’esercizio di un’opzione di acquisto di azioni per dipendenti con un prezzo di esercizio di $5.10, aumentando la sua proprietà Beneficial immediatamente dopo l’acquisizione a 49.023 azioni. Nella stessa data ha venduto 3.828 azioni a un prezzo medio ponderato di $21.5172 e 1.154 azioni a un prezzo medio ponderato di $22.2778, eseguite in conformità a un piano Rule 10b5-1 adottato il 05/15/2025. Dopo queste transazioni la sua proprietà Beneficial dichiarata è di 44.041 azioni. Le azioni dell’opzione vestono in 48 rate mensili uguali a partire dal 09/14/2023.

Stephen Feider, Director financiero de , reportó transacciones de insiders fechadas el 10/03/2025. Él adquirió 4,982 acciones en esa fecha mediante el ejercicio de una opción de compra de acciones para empleados con un precio de ejercicio de $5.10, elevando su propiedad beneficiaria a 49,023 acciones inmediatamente después de la adquisición. En la misma fecha vendió 3,828 acciones a un precio medio ponderado de $21.5172 y 1,154 acciones a un precio medio ponderado de $22.2778, ejecutadas conforme a un plan Rule 10b5-1 adoptado el 05/15/2025. Después de estas transacciones su propiedad beneficiaria reportada es de 44,041 acciones. Las acciones de opción visten en 48 cuotas mensuales iguales desde el 09/14/2023.

Stephen Feider, Beta Bionics, Inc. (BBNX)의 최고재무책임자(CFO)로서 내부자 거래를 2025년 10월 3일자로 보고했다. 그는 그 날짜에 직원 주식매수선택권 행사로 4,982주를 취득했고 행사가는 $5.10였으며, 취득 직후 유익한 소유 주식 수가 49,023주로 증가했다. 같은 날짜에 그는 3,828주를 가중평균가 $21.5172로, 1,154주를 가중평균가 $22.2778로 매도했고 이는 2025년 5월 15일에 채택된 Rule 10b5-1 계획에 따라 실행됐다. 이 거래 후 보고된 유익한 소유는 44,041주다. 옵션 주식은 2023년 9월 14일로부터 매달 48회로 균등하게 vest 된다.

Stephen Feider, directeur financier de Beta Bionics, Inc. (BBNX), a rapporté des transactions d’initiés datées du 10/03/2025. Il a acheté 4 982 actions à cette date par l’exercice d’une option d’achat d’actions pour employés avec un prix d’exercice de $5.10, portant sa propriété bénéficiaire à 49 023 actions immédiatement après l’acquisition. Le même jour, il a vendu 3 828 actions à un prix moyen pondéré de $21.5172 et 1 154 actions à un prix moyen pondéré de $22.2778, exécutées conformément à un plan Rule 10b5-1 adopté le 15/05/2025. Après ces transactions, sa propriété bénéficiaire déclarée est de 44 041 actions. Les actions d’options se vestent en 48 versements mensuels égaux à partir du 14/09/2023.

Stephen Feider, CFO von Beta Bionics, Inc. (BBNX), meldete Insider-Transaktionen datiert auf den 03.10.2025. Er erwarb an diesem Datum 4.982 Aktien durch Ausübung einer Mitarbeiteraktienoption zum Ausübungspreis von $5.10, wodurch sein Beneficial Ownership unmittelbar nach dem Erwerb auf 49.023 Aktien anstieg. Am selben Tag verkaufte er 3.828 Aktien zu einem gewichteten Durchschnittspreis von $21.5172 und 1.154 Aktien zu $22.2778, ausgeführt gemäß einem am 15/05/2025 adoptieren Rule 10b5-1-Plan. Nach diesen Transaktionen beträgt sein gemeldetes Beneficial Ownership 44.041 Aktien. Die Optionsaktien vesten in 48 gleichen monatlichen Teilbeträgen beginnend mit dem 14.09.2023.

ستيفن فيدر، المدير المالي لشركة Beta Bionics, Inc. (BBNX)، أبلغ عن معاملات داخلية بتاريخ 03/10/2025. قام باكتساب 4,982 سهماً في ذلك التاريخ من خلال ممارسة خيار شراء أسهم موظفين بسعر تنفيذ $5.10، مما رفع ملكيته المفيدة إلى 49,023 سهماً فور الاكتساب. في نفس التاريخ باع 3,828 سهماً بسعر متوسط مرجح قدره $21.5172 و 1,154 سهماً بسعر متوسط مرجح قدره $22.2778، وفقاً لخطة Rule 10b5-1 المعتمدة في 15/05/2025. بعد هذه المعاملات أصبح ملكه المفيد المبلغ عنه 44,041 سهماً. تتفكَّك أسهم الخيار في 48 دفعات شهرية متساوية ابتداءً من 14/09/2023.

Stephen Feider，Beta Bionics, Inc.（BBNX）的首席财务官，报告了日期为2025-10-03的内幕交易。该日期他通过行使员工股票期权以行权价$5.10购买了4,982股，使其实际受益所有权在收购后立即增至49,023股。同日他以加权平均价格$21.5172卖出< b>3,828股，并以加权平均价格$22.2778卖出< b>1,154股，这些交易根据于2025-05-15通过的Rule 10b5-1计划执行。经这些交易后，报告的实际持有量为44,041股。期权股票自2023-09-14起以48期等额分期 vest。

Positive
  • Transaction executed under a Rule 10b5-1 plan (adopted 05/15/2025), providing predetermined, non‑discretionary sale mechanics
  • Option exercise increased holdings by 4,982 shares at an exercise price of $5.10, showing use of vested compensation to acquire shares
Negative
  • Total beneficial ownership declined from 49,023 shares to 44,041 shares after the sales on 10/03/2025
  • CFO sold 4,982 shares in total (3,828 + 1,154), which may reduce insider share concentration

Insights

Concurrent option exercise and planned sales reduced ownership to 44,041 shares.

The CFO exercised an employee stock option to acquire $4,982 shares at an exercise price of $5.10 on 10/03/2025 while selling 3,828 and 1,154 shares at weighted averages of $21.5172 and $22.2778 under a Rule 10b5-1 plan adopted 05/15/2025. The filings show the mechanics: exercise increased holdings before pre‑planned sales reduced them to 44,041.

Dependencies and risks include the fact that sales were executed under a documented plan, which limits interpretive value regarding discretionary insider intent. Monitor quarterly filings and any future Form 4s for material changes in ownership or additional 10b5-1 activity within the next 12 months.

Option vesting schedule and exercise price indicate long‑dated compensation alignment.

The option underlying the acquired shares vests in 48 equal monthly installments measured from 09/14/2023, and the exercise price is $5.10. Post-exercise, the filing reports 69,695 total option shares referenced in Table II prior to the transaction adjustments shown.

Key items to watch: remaining unvested option tranches and future exercises that may dilute equity; review subsequent equity grants disclosed in proxy materials or Form 4s over the next 12 months to assess ongoing compensation dilution.

Stephen Feider, Chief Financial Officer di Beta Bionics, Inc. (BBNX), ha riportato transazioni insider datate 10/03/2025. Ha acquistato 4.982 azioni in quella data mediante l’esercizio di un’opzione di acquisto di azioni per dipendenti con un prezzo di esercizio di $5.10, aumentando la sua proprietà Beneficial immediatamente dopo l’acquisizione a 49.023 azioni. Nella stessa data ha venduto 3.828 azioni a un prezzo medio ponderato di $21.5172 e 1.154 azioni a un prezzo medio ponderato di $22.2778, eseguite in conformità a un piano Rule 10b5-1 adottato il 05/15/2025. Dopo queste transazioni la sua proprietà Beneficial dichiarata è di 44.041 azioni. Le azioni dell’opzione vestono in 48 rate mensili uguali a partire dal 09/14/2023.

Stephen Feider, Director financiero de , reportó transacciones de insiders fechadas el 10/03/2025. Él adquirió 4,982 acciones en esa fecha mediante el ejercicio de una opción de compra de acciones para empleados con un precio de ejercicio de $5.10, elevando su propiedad beneficiaria a 49,023 acciones inmediatamente después de la adquisición. En la misma fecha vendió 3,828 acciones a un precio medio ponderado de $21.5172 y 1,154 acciones a un precio medio ponderado de $22.2778, ejecutadas conforme a un plan Rule 10b5-1 adoptado el 05/15/2025. Después de estas transacciones su propiedad beneficiaria reportada es de 44,041 acciones. Las acciones de opción visten en 48 cuotas mensuales iguales desde el 09/14/2023.

Stephen Feider, Beta Bionics, Inc. (BBNX)의 최고재무책임자(CFO)로서 내부자 거래를 2025년 10월 3일자로 보고했다. 그는 그 날짜에 직원 주식매수선택권 행사로 4,982주를 취득했고 행사가는 $5.10였으며, 취득 직후 유익한 소유 주식 수가 49,023주로 증가했다. 같은 날짜에 그는 3,828주를 가중평균가 $21.5172로, 1,154주를 가중평균가 $22.2778로 매도했고 이는 2025년 5월 15일에 채택된 Rule 10b5-1 계획에 따라 실행됐다. 이 거래 후 보고된 유익한 소유는 44,041주다. 옵션 주식은 2023년 9월 14일로부터 매달 48회로 균등하게 vest 된다.

Stephen Feider, directeur financier de Beta Bionics, Inc. (BBNX), a rapporté des transactions d’initiés datées du 10/03/2025. Il a acheté 4 982 actions à cette date par l’exercice d’une option d’achat d’actions pour employés avec un prix d’exercice de $5.10, portant sa propriété bénéficiaire à 49 023 actions immédiatement après l’acquisition. Le même jour, il a vendu 3 828 actions à un prix moyen pondéré de $21.5172 et 1 154 actions à un prix moyen pondéré de $22.2778, exécutées conformément à un plan Rule 10b5-1 adopté le 15/05/2025. Après ces transactions, sa propriété bénéficiaire déclarée est de 44 041 actions. Les actions d’options se vestent en 48 versements mensuels égaux à partir du 14/09/2023.

Stephen Feider, CFO von Beta Bionics, Inc. (BBNX), meldete Insider-Transaktionen datiert auf den 03.10.2025. Er erwarb an diesem Datum 4.982 Aktien durch Ausübung einer Mitarbeiteraktienoption zum Ausübungspreis von $5.10, wodurch sein Beneficial Ownership unmittelbar nach dem Erwerb auf 49.023 Aktien anstieg. Am selben Tag verkaufte er 3.828 Aktien zu einem gewichteten Durchschnittspreis von $21.5172 und 1.154 Aktien zu $22.2778, ausgeführt gemäß einem am 15/05/2025 adoptieren Rule 10b5-1-Plan. Nach diesen Transaktionen beträgt sein gemeldetes Beneficial Ownership 44.041 Aktien. Die Optionsaktien vesten in 48 gleichen monatlichen Teilbeträgen beginnend mit dem 14.09.2023.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feider Stephen
(Last) (First) (Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/03/2025 M 4,982 A $5.1 49,023 D
Common Stock 10/03/2025 S(1) 3,828 D $21.5172(2) 45,195 D
Common Stock 10/03/2025 S(1) 1,154 D $22.2778(3) 44,041 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $5.1 10/03/2025 M 4,982 (4) 09/13/2033 Common Stock 4,982 $0 69,695 D
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
2. The weighted average sale price for the transaction reported was $21.5172 and the range of prices were between $21.04 and $22.0144. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. The weighted average sale price for the transaction reported was $22.2778 and the range of prices were between $22.0438 and $22..47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
/s/ Stephen Feider 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Beta Bionics CFO Stephen Feider file on Form 4 (BBNX)?

The filing reports an option exercise for 4,982 shares at an exercise price of $5.10 and sales of 3,828 and 1,154 shares on 10/03/2025.

Were the sales executed under a Rule 10b5-1 plan?

Yes. The seller disclosed the transactions were made pursuant to a Rule 10b5-1 plan adopted on 05/15/2025.

What is Stephen Feider’s beneficial ownership after these transactions?

The Form 4 reports final beneficial ownership of 44,041 shares following the reported transactions on 10/03/2025.

What was the weighted average sale price for the reported sales?

The sales had weighted average prices of $21.5172 (range $21.04–$22.0144) and $22.2778 (range $22.0438–$22.47), respectively.

What are the vesting terms for the exercised option?

The shares subject to the option vest in 48 equal monthly installments measured from 09/14/2023.

When was the Form 4 signed?

The Form 4 is signed by Stephen Feider and dated 10/07/2025.
Stock BBNX logo
Beta Bionics, Inc.

NASDAQ:BBNX

BBNX Rankings

#2761 Ranked by Market Cap
N/A Ranked by Dividends

BBNX Latest News

BBNX Latest SEC Filings

BBNX Stock Data

962.86M
41.60M
6.49%
104.92%
7.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE